Mok Oh

1.7k total citations · 1 hit paper
25 papers, 619 citations indexed

About

Mok Oh is a scholar working on Oncology, Surgery and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mok Oh has authored 25 papers receiving a total of 619 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Oncology, 7 papers in Surgery and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mok Oh's work include Prostate Cancer Treatment and Research (6 papers), BRCA gene mutations in cancer (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Mok Oh is often cited by papers focused on Prostate Cancer Treatment and Research (6 papers), BRCA gene mutations in cancer (5 papers) and Health Systems, Economic Evaluations, Quality of Life (5 papers). Mok Oh collaborates with scholars based in United States, Japan and Belgium. Mok Oh's co-authors include Ivo Abraham, Ali McBride, Jennifer Martin, Joanne Jeter, Jung Wook Park, Kohei Shitara, Manish A. Shah, Joseph Chao, David H. Ilson and Giuseppe Aprile and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

Mok Oh

23 papers receiving 608 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

2023 342 citations Kohei Shitara, Florian Lordick et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mok Oh United States	8	300	263	147	114	108	25	619
Andriy Rusyn Ukraine	9	212 0.7×	285 1.1×	108 0.7×	38 0.3×	62 0.6×	16	485
Claudia Ligorio Italy	9	256 0.9×	274 1.0×	70 0.5×	288 2.5×	87 0.8×	11	619
S-E. Al-Batran Germany	12	326 1.1×	380 1.4×	175 1.2×	217 1.9×	66 0.6×	55	711
Yusuke Okuda Japan	11	91 0.3×	187 0.7×	127 0.9×	136 1.2×	113 1.0×	32	539
Benjamin L. Green United States	12	108 0.4×	161 0.6×	93 0.6×	107 0.9×	67 0.6×	26	499
Patricio Yañez Chile	8	586 2.0×	600 2.3×	303 2.1×	87 0.8×	69 0.6×	14	957
Hans‐Peter Bruch Germany	13	142 0.5×	218 0.8×	258 1.8×	184 1.6×	135 1.3×	30	614
Mai Iwaya Japan	10	81 0.3×	120 0.5×	86 0.6×	62 0.5×	29 0.3×	65	313
Antonio d’Amati Italy	13	91 0.3×	99 0.4×	50 0.3×	122 1.1×	50 0.5×	63	461

Countries citing papers authored by Mok Oh

Since Specialization

Citations

This map shows the geographic impact of Mok Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mok Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mok Oh more than expected).

Fields of papers citing papers by Mok Oh

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mok Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mok Oh. The network helps show where Mok Oh may publish in the future.

Co-authorship network of co-authors of Mok Oh

This figure shows the co-authorship network connecting the top 25 collaborators of Mok Oh. A scholar is included among the top collaborators of Mok Oh based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mok Oh. Mok Oh is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Lordick, F., et al.. (2026). Impact and effective management of nausea/vomiting on patients treated with zolbetuximab + chemotherapy: insights from the phase III SPOTLIGHT and GLOW studies. ESMO Open. 11(2). 105931–105931.

Shitara, Kohei, et al.. (2024). Management of nausea and vomiting (N/V) following first-line (1L) zolbetuximab + chemotherapy treatment in claudin-18.2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Analysis from the phase 3 SPOTLIGHT and GLOW studies.. Journal of Clinical Oncology. 42(3_suppl). 372–372. 10 indexed citations

Shitara, Kohei, Florian Lordick, Yung‐Jue Bang, et al.. (2023). Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial. The Lancet. 401(10389). 1655–1668. 342 indexed citations breakdown →

Lordick, Florian, Eric Van Cutsem, Kohei Shitara, et al.. (2023). 1530P Health-related quality of life (hrqol) in patients with claudin-18 isoform 2-positive (CLDN18.2+) locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma: Results from SPOTLIGHT and GLOW. Annals of Oncology. 34. S860–S861. 1 indexed citations

González, Juan Marcos, Arijit Ganguli, Alicia K. Morgans, et al.. (2023). Discrete-Choice Experiment to Understand the Preferences of Patients with Hormone-Sensitive Prostate Cancer in the USA, Canada, and the UK. Patient. 16(6). 607–623. 3 indexed citations

Oh, Mok, Ali McBride, Sandipan Bhattacharjee, et al.. (2023). The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention. Expert Review of Pharmacoeconomics & Outcomes Research. 23(3). 309–316. 5 indexed citations

Tombal, Bertrand, Cora N. Sternberg, Maha Hussain, et al.. (2022). Matching-adjusted indirect treatment comparison of the efficacy of enzalutamide versus apalutamide for the treatment of nonmetastatic castration-resistant prostate cancer. ESMO Open. 7(3). 100510–100510. 4 indexed citations

McBride, Ali, Mok Oh, Christopher S. Lee, et al.. (2022). Meta-Analysis of Same-Day Pegfilgrastim Administration Stratified by Myelotoxic Febrile Neutropenia Risk and Tumor Type. Journal of the Advanced Practitioner in Oncology. 13(8). 796–811. 2 indexed citations

Soileau, Michael J., Fernando Pagán, Alfonso Fasano, et al.. (2022). Comparative Effectiveness of Carbidopa–Levodopa Enteral Suspension and Deep Brain Stimulation on Parkinson’s Disease-Related Pill Burden Reduction in Advanced Parkinson’s Disease: A Retrospective Real-World Cohort Study. Neurology and Therapy. 11(2). 851–861. 7 indexed citations

10.

George, Daniel J., Arijit Ganguli, Alicia K. Morgans, et al.. (2022). Patient preferences for treatment and outcomes in hormone-sensitive prostate cancer (HSPC).. Journal of Clinical Oncology. 40(16_suppl). e18757–e18757. 2 indexed citations

11.

Beer, Tomasz M., Fred Saad, Cora N. Sternberg, et al.. (2021). Network meta-analysis (NMA) comparing the efficacy of enzalutamide versus apalutamide, darolutamide, and bicalutamide for treatment of nonmetastatic (nm) castration-resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 39(6_suppl). 101–101. 4 indexed citations

12.

Riaz, Irbaz Bin, Abdulaali R. Almutairi, Yuan Yao, et al.. (2020). Cost-effectiveness of novel antiandrogens (AAs) for treatment of nonmetastatic castrate-resistant prostate cancer (nmCRPC).. Journal of Clinical Oncology. 38(15_suppl). 5583–5583. 5 indexed citations

13.

Almutairi, Abdulaali R., Mok Oh, Jennifer Martin, et al.. (2020). Exposure to proton pump inhibitors and risk of pancreatic cancer: a meta-analysis. Expert Opinion on Drug Safety. 19(3). 327–334. 14 indexed citations

14.

Oh, Mok, et al.. (2020). Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association. International Journal of Pharmacy Practice. 29(1). 21–28. 12 indexed citations

15.

Oh, Mok, Joanne Jeter, Jennifer Martin, et al.. (2019). The association of BRCA1 and BRCA2 mutations with prostate cancer risk, frequency, and mortality: A meta‐analysis. The Prostate. 79(8). 880–895. 90 indexed citations

16.

Oh, Mok, Abdulaali R. Almutairi, Hani M. Babiker, et al.. (2019). 30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa).. Journal of Clinical Oncology. 37(15_suppl). e16597–e16597. 1 indexed citations

17.

Oh, Mok, Bernard L. Marini, Anthony J. Perissinotti, et al.. (2019). Bayesian network meta-analysis (NMA) of complete remission without or with incomplete hematologic recovery (CR/CRi) to CPX-351, FLAG, and standard 7+3 (7+3) chemotherapy in the treatment of newly diagnosed secondary acute myeloid leukemia (sAML).. Journal of Clinical Oncology. 37(15_suppl). e18514–e18514. 1 indexed citations

18.

Almutairi, Abdulaali R., Mok Oh, Clara Curiel‐Lewandrowski, et al.. (2018). Economic Evaluation of Talimogene Laherparepvec Plus Ipilimumab Combination Therapy vs Ipilimumab Monotherapy in Patients With Advanced Unresectable Melanoma. JAMA Dermatology. 155(1). 22–22. 24 indexed citations

19.

Oh, Mok, Ali McBride, Seongseok Yun, et al.. (2018). BRCA1andBRCA2Gene Mutations and Colorectal Cancer Risk: Systematic Review and Meta-analysis. JNCI Journal of the National Cancer Institute. 110(11). 1178–1189. 86 indexed citations

20.

Yeo, Jeong Kyun, et al.. (2012). 562 The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: A prospective study. European Urology Supplements. 11(1). e562–e562a. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact